Ge Long Hui·2026-03-12 09:06Group 1 - China Biologic Products (01177.HK) announced that its subsidiary, Chengda Tianqing, has completed the interim analysis of the Phase III clinical study for TQB3454, an IDH1 inhibitor for advanced cholangiocarcinoma with IDH1 mutations, achieving the predefined efficacy thresholds for progression-free survival (PFS) and overall survival (OS) [1] - The study, TQB3454-III-01, is a randomized, double-blind, placebo-controlled, multi-center Phase III trial aimed at evaluating the efficacy and safety of TQB3454 in patients with advanced cholangiocarcinoma who have failed previous treatments [1] - The independent data monitoring committee (IDMC) determined that TQB3454 significantly reduces the risk of disease progression or death compared to the control group, significantly extending both PFS and OS [1] Group 2 - Cholangiocarcinoma (BTC) accounts for approximately 3% of all digestive system tumors, with over 200,000 new cases globally in 2021, and its incidence is on the rise [2] - BTC primarily consists of adenocarcinoma, characterized by high malignancy and poor prognosis, with a five-year survival rate of less than 5% [2] - IDH1 inhibitors are crucial for the precision treatment of cholangiocarcinoma, and currently, there are no approved drugs targeting this pathway in China, indicating a significant unmet clinical need [2]